Anbio Biotechnology
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q4 23 | Q2 24 | Q4 24 | Q3 25 | Q1 26 |
|---|---|---|---|---|---|---|
| – | -157.8% | – | +147.8% | – | – | |
| – | -62.7% | – | – | – | – | |
| – | -394.9% | – | – | – | – | |
| – | +50.0% | -63.1% | +438.7% | -100.0% | – | |
| – | -90.6% | -7.1% | +44.3% | – | – | |
| – | – | -154.0% | +100.5% | – | – | |
| – | – | – | +133.5% | – | – | |
| – | -157.8% | – | +147.8% | – | – |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.